Royal Philips has agreed to acquire medical technology company BioTelemetry for $72 per share in a deal that values the Pennsylvania-based business at roughly $2.8 billion, including debt. The purchase price marks a 16.5% premium to BioTelemetry's closing stock price Thursday. BioTelemetry specializes in remote cardiac diagnostic and monitoring services.